GALT — what changed in the latest 10-Q
A section-by-section comparison of GALT's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-14 vs the prior 10-Q · 2026-05-15
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +5 | −3 | ~6 | 60 |
| Market risk (Item 3) | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Controls & procedures | Text added/removed | 0 | 0 | ~2 | 4 |
| Risk factors | No paragraph-level changes | 0 | 0 | 0 | 1 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Legal proceedings, Other information
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-14
The Company submitted a Type C meeting request in the first quarter of 2026. Subsequently, FDA granted an in-person Type C meeting which was held in the second quarter of 2026. The Company reached agreement with FDA on the primary endpoint and regulatory path forward for the potential full approval …
During the six months ended June 30, 2026, other income and expense consisted of $65,000 of interest income offset by interest expense and amortization of debt discounts on convertible notes payable and convertible line of credit of $3,992,000 and change in fair value of derivatives of $2,173,000.
During the year ended June 30, 2025, other income and expense consisted of $61,000 of interest income offset by interest expense and amortization of debt discounts on convertible notes payable and convertible line of credit of $3,570,000 and change in fair value of derivatives of $1,121,000.
Since our inception on July 10, 2000, we have financed our operations from proceeds of public and private offerings of debt and equity. As of June 30, 2026, we raised a net total of $342 million from these offerings. At June 30, 2026, the Company had $13.3 million of unrestricted cash and cash equiv…
Net cash used in operations decreased by $7,986,000 to $6,305,000 for the six months ended June 30, 2026, as compared to $14,291,000 for the six months ended June 30, 2025. Cash operating expenses decreased principally due to the completion of our NAVIGATE clinical trial with belapectin in 2025.
Text removed vs the prior filing · source: 10-Q · 2026-05-15
The Company submitted a Type C meeting request in the first quarter of 2026. Subsequently, FDA granted an in-person Type C meeting to be held in the second quarter of 2026.
Since our inception on July 10, 2000, we have financed our operations from proceeds of public and private offerings of debt and equity. As of March 31, 2026, we raised a net total of $341 million from these offerings. At March 31, 2026, the Company had $14.1 million of unrestricted cash and cash equ…
Net cash used in operations decreased by $3,823,000 to $3,866,000 for the three months ended March 31, 2026, as compared to $7,689,000 for the three months ended March 31, 2025. Cash operating expenses decreased principally due to the completion of our NAVIGATE clinical trial with belapectin in 2025…
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice